NCT05138107尚未招募不适用
Prospective Placebo-controlled Study of Synochi Scar Spray
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Synochi, LLC
- 入组人数
- 28
- 主要终点
- improvement of cosmetic appearance Synochi Scar Spray versus Placebo
研究概览
简要总结
Randomized, double-blind, placebo controlled, prospective, split-scar study of severe burn victims with autologous skin transplants. 9 months intervention time and 3 months follow-up, photographic scar documentation, self-and observer questionnaires throughout
详细描述
Interventional, comparative, prospective, evaluator blinded, randomized, placebo- controlled, split-scar model longitudinal study including 28-31 healthy study participants (See Section 6 Statistical Considerations) with both the original burn scar area that is the skin graft recipient area and the skin graft donor site.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
blinded
入排标准
- 年龄范围
- 22 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Study participants are healthy study participants from any sex and race, but must be between 22 and 50 years of age at the time of consent.
- •Study participants must be willing to provide written informed consent and be able to read, write, speak, and understand the test procedures in English. Ability will be documented with a doctors' note.
- •Study participants must be willing to sign a Photo and Video Release Form.
- •Study participants must possess both the original burn scar area that is the skin graft recipient area and the skin graft donor site that is at least around 6 weeks old that have not been altered in any way prior (No prior scar reduction surgery, laser, steroid injections, silicone sheets or anything of the like).
- •Study participants must be in good general health.
排除标准
- •- Study participants must not currently be under the care of a medical or cosmetic professional for care of the scar to be evaluated in testing.
- •They must be without medical diagnosis of medicated or uncontrolled diabetes, hepatitis B, hepatitis C, an organ transplant, a heart murmur, mitral valve prolapse with heart murmur, fibromyalgia, ulcerative colitis, Crohn's disease, moderate to severe asthma (requiring daily use of systemic steroid medication, nasal steroids are permitted), an immunocompromised condition such as AIDS (or HIV positive), lupus, or medicated multiple sclerosis, not pregnant or trying to become pregnant, lactating, transplant recipient on immunosuppression, the BMI should be 19 - <
- •Have any type of vascular disease (e.g., arteriosclerosis, Raynaud's Syndrome, or peripheral venous disease) or any blood clotting disorders.
- •Have participated in another clinical study within the past 14 days, or be currently participating in another clinical study.
- •Have or have someone in their household with known sensitivities or allergies to latex (rubber), bar or liquid cleansing products, serums, moisturizers, lotions, creams, preservatives, fragrances, cosmetics, or common ingredients used in traditional Chinese medicine, including Notopterygium root (Notopterygium Incisum), sweetgum fruit ( Liquidambaris Fructus), bur reed rhizome (Rhizoma Sparganii), corydalis rhizome (Rhizoma Corydalis), ledebouriella root / siler (Radix Saposhnikoviae), costus root (Radix Auklandiae Lappae), rehmannia root (Radix Rehmanniae Preparata), deer horn gelatin/glue (Gelatinum Cornu Cervi), safflower (Carthamus Tinctorius), forsythia fruit (Fructus Forsythiae), red earthworm (Lumbricus), trichosanthes root (Radix Trichosanthes), Chinese motherwort (Herba Leonuri), millettia vine (Caulis Spatholobi), zedoary rhizome (Rhizoma Curcumae), turmeric tuber (Radix Curcumae), rhubarb (Radix et Rhizoma Rhei), white peony root (Radix Paeoniae Alba), white mustard seed (Semen Sinapis Albae), Chinese angelica root (Angelicae sinensis Radix), cinnamon twig (Ramulus Cinnamomi), red peony (Radix Paeoniae Rubra), peach kernel (Semen Persicae), astragalus (Radix Astragali), frankincense resin (Resina Boswelliae Carterii), myrrh (Resina Commiphorae Myrrhae), sandalwood (Santalum Album), radiz notoginseng (Radix Notoginseng), spine of honey locust (Spina Gleditsiae), silkworm (Bombyx Batryticatus)
- •Have experienced hives (raised welts) as a reaction to anything contacting their skin.
- •Not be diagnosed with a medical condition that, in the opinion of the Principal Investigator, would preclude participation.
- •Not be unwilling to fulfill the performance requirements of the study.
- •Not be direct employees, in a relationship with, or family of the sponsor or Principal Investigator.
- •Not be participating in any other clinical trial during the time of this clinical trial.
- •Medication: Not be receiving any steroid medications (including those used to treat asthma) other than for contraception, hormone therapy, or menopausal purposes. No chemotherapeutic agents or any medication that interferes with wound healing (rheumatologic agents, Emgality or Aimovig).
结局指标
主要结局
improvement of cosmetic appearance Synochi Scar Spray versus Placebo
时间窗: 12 month study time frame
Section I of the Patient Scar Assessment Questionnaire (9 questions) minimum 9 points, maximum 36 with higher ratings indicating less improvement of cosmetic appearance
次要结局
- evaluate the safety of Synochi Scar Spray(12 month study time frame)
研究者
相似试验
进行中（未招募）
2 期
Study of Suramin in Subjects With Furosemide-Resistant AKIAcute Kidney InjuryNCT04496596Rediscovery Life Sciences68
招募中
不适用
Nafamostat Efficacy in Phase 3 Registrational CRRT StudyAcute Kidney InjuryNCT06150742Talphera, Inc70
Unknown
2 期
Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal WoundsWoundsOther Ulcers Wounds and Skin ProblemsNCT02839226Arava Bio Tech Ltd.60
Unknown
不适用
Effects of Sulforaphane in Patients With Prodromal to Mild Alzheimer's DiseaseAlzheimer DiseaseNCT04213391Second Affiliated Hospital, School of Medicine, Zhejiang University160
进行中（未招募）
3 期
Effect of EPA-FFA on Polypectomy in Familial Adenomatous PolyposisFamilial Adenomatous PolyposisNCT03806426S.L.A. Pharma AG204